SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                -----------------

                                    Form 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934


       Date of Report (Date of earliest event reported): December 21, 2001


                                  XTRANA, INC.
               (Exact Name of Registrant as Specified in Charter)


      Delaware                       0-17714                    58-1729436
(State or Other Jurisdiction       (Commission                 (IRS Employer
   of Incorporation)               File Number)              Identification No.)


                          590 Burbank Street, Suite 205
                           Broomfield, Colorado 80020
                    (Address of Principal Executive Offices)

                                 (303) 466-4424
                         (Registrant's Telephone Number)


<PAGE>


ITEM 2.  ACQUISITION OR DISPOSITION OF ASSETS

     As  previously  reported on November  15,  2001,  Xtrana,  Inc., a Delaware
corporation (the "Registrant")  entered into an agreement to sell its Hemostasis
business  segment to Trinity  Biotech plc, an Irish public limited  company.  On
December 21, 2001, the Registrant  completed the sale of its Hemostasis business
pursuant  to the  terms  of  the  sale  agreement.  The  total  sale  price  was
approximately $6,250,000, which consisted of cash in the amount of $3,658,500, a
secured  promissory  note in the  amount  of  $855,200  (subject  to  adjustment
pursuant to the sale  agreement)  payable 12 months  after the closing  date,  a
secured  promissory note in the amount of $1,166,200 payable 24 months after the
closing date, and a secured promissory note in the amount of $570,100 payable 36
months after the closing date.

     The sale was approved by the Registrant's stockholders at a special meeting
on  December  20,  2001.  The  purchase  price  was  determined  by  arms-length
negotiation.  The Registrant's  press release announcing the closing of the sale
is filed herewith as Exhibit 99 and incorporated herein by reference.



ITEM 7.  FINANCIAL STATEMENTS AND EXHIBITS

     (a)  Financial Statements. None.

     (b)  Pro Forma Financial Information. Not filed with this initial report on
          Form 8-K; to be filed by amendment no later than February 19, 2002.

     (c)  Exhibits.

          Exhibit 2

          Asset  Purchase   Agreement  dated  November  9,  2001,   between  the
          Registrant and Trinity Biotech plc  (incorporated  by reference to the
          Registrant's  Definitive Proxy Statement filed with the Securities and
          Exchange Commission on November 20, 2001)

          Exhibit 99

          Press Release of the Registrant  dated  December 21, 2001,  announcing
          the sale of Registrant's Hemostasis business segment


                                       2


<PAGE>


                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


January 7, 2002                        XTRANA, INC.



                                       By:  /S/ TIMOTHY DAHLTORP
                                            ------------------------------------
                                            Timothy Dahltorp
                                            Chief Executive Officer
                                            Chief Financial Officer


                                       3


<PAGE>


                                  EXHIBIT INDEX

Exhibit                                                              Page Number

99           Press Release of the Registrant Dated                        5
             December 21, 2001, Announcing the
             Sale of the Registrant's Hemostasis Business


                                       4


<PAGE>


EXHIBIT 99



CONTACTS:         Timothy Dahltorp                   Carol Hill
                  Chief Executive Officer            Corporate Communications
                  (303) 466-4424                     (805) 654-0643


FOR IMMEDIATE RELEASE


               XTRANA CLOSES THE SALE OF ITS HEMOSTASIS OPERATIONS

Broomfield,  CO - December 21, 2001-- XTRANA, Inc. (OTCBB:XTRN)  announced today
that it has closed the sale of the assets of its Hemostasis  business to Trinity
Biotech plc (NASDAQ:TRIB) for $6,250,000 in cash and secured notes.

Completion of the sale was subject to a number of closing conditions,  including
the  approval of a majority of Xtrana's  stockholders.  At a Special  Meeting of
Xtrana  stockholders  held on December 20, the  transaction  was  overwhelmingly
approved.

Timothy Dahltorp,  Xtrana's chief executive officer, commented, "The sale of the
Hemostasis  operations  is a very  important  step  forward for our nucleic acid
diagnostics business.  Not only will it provide the capital necessary to support
the development and  commercialization of our nucleic acid technologies,  but it
also clarifies our market  identity and allows us to focus all of our efforts on
our cutting edge  genomics  technologies."

Xtrana's  mission is to simplify the  analysis of DNA/RNA,  so that nucleic acid
based  detection  systems  can be utilized  in  point-of-care,  point-of-service
applications. The proprietary assays developed by Xtrana are designed to be easy
to use outside of a traditional  molecular biology laboratory at a cost per test
that is competitive  with existing  rapid test  technologies.  These  diagnostic
tests are intended for use in drug  discovery,  detection of  environmental  and
food  contaminants,  forensics and identity testing,  human and animal diseases,
genetic  predisposition to disease, and other applications.  The Company's first
commercial nucleic acid product is Xtra Amp(TM), DNA or RNA extraction kits that
enable high throughput  extraction in as little as 3 minutes,  versus  competing
technologies  that can take 30 minutes to 3 hours.  To learn more about  Xtrana,
visit the Company's website at www.xtrana.com.

This Press Release contains forward-looking  statements (identified by the words
"estimate,"  "anticipate," "expect," "believe," and similar expressions),  which
are based upon management's  current  expectations and speak only as of the date
made. These forward-looking  statements are subject to risks,  uncertainties and
factors that could cause actual  results to differ  materially  from the results
anticipated in the forward-looking  statements and include,  but are not limited
to, competitors'  pricing strategies and technological  innovations,  changes in
health care and government  regulations,  litigation  claims,  foreign  currency
fluctuation,  product  acceptance,  as well as other  factors  discussed  in the
Company's last Report on Form 10-KSB.

                                      # # #


                                       5
[{"type": "8-K", "sequence": "1", "filename": "x8k010702.txt", "description": "8-K 010702", "secsgml_size_bytes": 7186}]
{"company-data": {"conformed-name": "XTRANA INC", "cik": "0000830736", "assigned-sic": "2835", "irs-number": "581729436", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-14257", "film-number": "2503343"}, "business-address": {"street1": "590 BURBANK STREET", "street2": "SUITE 205", "city": "BROOMFIELD", "state": "CO", "zip": "80020", "phone": "3034664424"}, "mail-address": {"street1": "590 BURBANK STREET", "street2": "SUITE 205", "city": "BROOMFIELD", "state": "CO", "zip": "80020"}, "former-company": [{"former-conformed-name": "BIOPOOL INTERNATIONAL INC", "date-changed": "19920703"}, {"former-conformed-name": "CYTRX BIOPOOL LTD", "date-changed": "19890716"}]}
SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                -----------------

                                    Form 8-K

                                 CURRENT REPORT
                       PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): December 21, 2001

                                  XTRANA, INC.
               (Exact Name of Registrant as Specified in Charter)

      Delaware                       0-17714                    58-1729436
(State or Other Jurisdiction       (Commission                 (IRS Employer
   of Incorporation)               File Number)              Identification No.)

                          590 Burbank Street, Suite 205
                           Broomfield, Colorado 80020
                    (Address of Principal Executive Offices)

                                 (303) 466-4424
                         (Registrant's Telephone Number)
ITEM 2.  ACQUISITION OR DISPOSITION OF ASSETS

     As  previously  reported on November  15,  2001,  Xtrana,  Inc., a Delaware
corporation (the "Registrant")  entered into an agreement to sell its Hemostasis
business  segment to Trinity  Biotech plc, an Irish public limited  company.  On
December 21, 2001, the Registrant  completed the sale of its Hemostasis business
pursuant  to the  terms  of  the  sale  agreement.  The  total  sale  price  was
approximately $6,250,000, which consisted of cash in the amount of $3,658,500, a
secured  promissory  note in the  amount  of  $855,200  (subject  to  adjustment
pursuant to the sale  agreement)  payable 12 months  after the closing  date,  a
secured  promissory note in the amount of $1,166,200 payable 24 months after the
closing date, and a secured promissory note in the amount of $570,100 payable 36
months after the closing date.

     The sale was approved by the Registrant's stockholders at a special meeting
on  December  20,  2001.  The  purchase  price  was  determined  by  arms-length
negotiation.  The Registrant's  press release announcing the closing of the sale
is filed herewith as Exhibit 99 and incorporated herein by reference.

ITEM 7.  FINANCIAL STATEMENTS AND EXHIBITS

     (a)  Financial Statements. None.

     (b)  Pro Forma Financial Information. Not filed with this initial report on
          Form 8-K; to be filed by amendment no later than February 19, 2002.

     (c)  Exhibits.

          Exhibit 2

          Asset  Purchase   Agreement  dated  November  9,  2001,   between  the
          Registrant and Trinity Biotech plc  (incorporated  by reference to the
          Registrant's  Definitive Proxy Statement filed with the Securities and
          Exchange Commission on November 20, 2001)

          Exhibit 99

          Press Release of the Registrant  dated  December 21, 2001,  announcing
          the sale of Registrant's Hemostasis business segment

                                       2
SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

January 7, 2002                        XTRANA, INC.

                                       By:  /S/ TIMOTHY DAHLTORP
                                            ------------------------------------
                                            Timothy Dahltorp
                                            Chief Executive Officer
                                            Chief Financial Officer

                                       3
EXHIBIT INDEX

Exhibit                                                              Page Number

99           Press Release of the Registrant Dated                        5
             December 21, 2001, Announcing the
             Sale of the Registrant's Hemostasis Business

                                       4
EXHIBIT 99

CONTACTS:         Timothy Dahltorp                   Carol Hill
                  Chief Executive Officer            Corporate Communications
                  (303) 466-4424                     (805) 654-0643

FOR IMMEDIATE RELEASE

               XTRANA CLOSES THE SALE OF ITS HEMOSTASIS OPERATIONS

Broomfield,  CO - December 21, 2001-- XTRANA, Inc. (OTCBB:XTRN)  announced today
that it has closed the sale of the assets of its Hemostasis  business to Trinity
Biotech plc (NASDAQ:TRIB) for $6,250,000 in cash and secured notes.

Completion of the sale was subject to a number of closing conditions,  including
the  approval of a majority of Xtrana's  stockholders.  At a Special  Meeting of
Xtrana  stockholders  held on December 20, the  transaction  was  overwhelmingly
approved.

Timothy Dahltorp,  Xtrana's chief executive officer, commented, "The sale of the
Hemostasis  operations  is a very  important  step  forward for our nucleic acid
diagnostics business.  Not only will it provide the capital necessary to support
the development and  commercialization of our nucleic acid technologies,  but it
also clarifies our market  identity and allows us to focus all of our efforts on
our cutting edge  genomics  technologies."

Xtrana's  mission is to simplify the  analysis of DNA/RNA,  so that nucleic acid
based  detection  systems  can be utilized  in  point-of-care,  point-of-service
applications. The proprietary assays developed by Xtrana are designed to be easy
to use outside of a traditional  molecular biology laboratory at a cost per test
that is competitive  with existing  rapid test  technologies.  These  diagnostic
tests are intended for use in drug  discovery,  detection of  environmental  and
food  contaminants,  forensics and identity testing,  human and animal diseases,
genetic  predisposition to disease, and other applications.  The Company's first
commercial nucleic acid product is Xtra Amp(TM), DNA or RNA extraction kits that
enable high throughput  extraction in as little as 3 minutes,  versus  competing
technologies  that can take 30 minutes to 3 hours.  To learn more about  Xtrana,
visit the Company's website at www.xtrana.com.

This Press Release contains forward-looking  statements (identified by the words
"estimate,"  "anticipate," "expect," "believe," and similar expressions),  which
are based upon management's  current  expectations and speak only as of the date
made. These forward-looking  statements are subject to risks,  uncertainties and
factors that could cause actual  results to differ  materially  from the results
anticipated in the forward-looking  statements and include,  but are not limited
to, competitors'  pricing strategies and technological  innovations,  changes in
health care and government  regulations,  litigation  claims,  foreign  currency
fluctuation,  product  acceptance,  as well as other  factors  discussed  in the
Company's last Report on Form 10-KSB.

                                      # # #

                                       5